Multicenter phase I/II study of abemaciclib and ramucirumab in metastatic gastroesophageal adenocarcinoma (GEA): CDK4/6 and cyclin D1 alterations as a predictor of response and survival.
There are many hot conversations in biopharma today: market access, AI, transforming field operations. ClinicalMind’s Tom Sproat and 11Ten’s James Lewis discuss how leaders in biopharma can move these ...
Kirin Holdings management has avoided addressing significant questions on logic and viability of KV2027 “bridging” strategy LONDON--(BUSINESS WIRE)--Independent Franchise Partners, LLP (“Franchise ...
AUSTIN, TX - March 16, 2026 (NEWMEDIAWIRE) - In the intricate landscape of modern business, a notable disconnect often arises between the strategies set forth by executives and the actual execution of ...
The merits of strategy are not in form but in execution. Strategies remain incomplete until handed off and executed—often to people uninvolved in the planning process. These individuals are crucial ...
The hospitality business has many insights to offer to the healthcare sector, even though at first glance, these two industries may seem worlds apart. During a May Becker’s Hospital Review podcast, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results